JP6395611B2 - チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 - Google Patents

チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 Download PDF

Info

Publication number
JP6395611B2
JP6395611B2 JP2014561051A JP2014561051A JP6395611B2 JP 6395611 B2 JP6395611 B2 JP 6395611B2 JP 2014561051 A JP2014561051 A JP 2014561051A JP 2014561051 A JP2014561051 A JP 2014561051A JP 6395611 B2 JP6395611 B2 JP 6395611B2
Authority
JP
Japan
Prior art keywords
cell
cells
chop2
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014561051A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510759A5 (https=
JP2015510759A (ja
Inventor
ズオ−フア パン，
ズオ−フア パン，
Original Assignee
ウェイン・ステート・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウェイン・ステート・ユニバーシティー filed Critical ウェイン・ステート・ユニバーシティー
Publication of JP2015510759A publication Critical patent/JP2015510759A/ja
Publication of JP2015510759A5 publication Critical patent/JP2015510759A5/ja
Application granted granted Critical
Publication of JP6395611B2 publication Critical patent/JP6395611B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2014561051A 2012-03-05 2013-03-05 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法 Active JP6395611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
US61/606,663 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018082403A Division JP2018134098A (ja) 2012-03-05 2018-04-23 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法

Publications (3)

Publication Number Publication Date
JP2015510759A JP2015510759A (ja) 2015-04-13
JP2015510759A5 JP2015510759A5 (https=) 2016-04-28
JP6395611B2 true JP6395611B2 (ja) 2018-09-26

Family

ID=47892055

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014561051A Active JP6395611B2 (ja) 2012-03-05 2013-03-05 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP2018082403A Withdrawn JP2018134098A (ja) 2012-03-05 2018-04-23 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP2019123061A Pending JP2019193656A (ja) 2012-03-05 2019-07-01 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018082403A Withdrawn JP2018134098A (ja) 2012-03-05 2018-04-23 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP2019123061A Pending JP2019193656A (ja) 2012-03-05 2019-07-01 チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法

Country Status (16)

Country Link
US (3) US10947281B2 (https=)
EP (1) EP2822964B1 (https=)
JP (3) JP6395611B2 (https=)
KR (1) KR102137717B1 (https=)
CN (2) CN104334575A (https=)
AU (4) AU2013230112A1 (https=)
CA (1) CA2866405A1 (https=)
DK (1) DK2822964T3 (https=)
EA (1) EA201491643A1 (https=)
ES (1) ES2703324T3 (https=)
HU (1) HUE040487T2 (https=)
MX (1) MX360085B (https=)
NZ (1) NZ629843A (https=)
PL (1) PL2822964T3 (https=)
PT (1) PT2822964T (https=)
WO (1) WO2013134295A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2011140279A1 (en) 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
AU2013230112A1 (en) 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use
US9730888B2 (en) 2013-03-14 2017-08-15 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
JP6469669B2 (ja) 2013-07-08 2019-02-13 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ オキシムエステル光開始剤
AU2015229464B2 (en) 2014-03-11 2021-07-22 Wayne State University A modified mGluR6 promoter and methods of use
RU2018142273A (ru) 2016-05-03 2020-06-03 Чжо-хуа Пань Способ улучшения опосредованной вирусами доставки генов в глаз с использованием ингибиторов протеасом
WO2017207745A1 (en) * 2016-06-03 2017-12-07 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Mutant light-inducible ion channel of channelrhodopsin
CA3034887A1 (en) * 2016-08-29 2018-03-08 Wayne State University Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
WO2018106369A2 (en) * 2016-11-06 2018-06-14 Nanoscope Technologies Llc Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof
EP3609518A1 (en) * 2017-04-12 2020-02-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
SI3720428T1 (sl) * 2017-12-04 2023-05-31 Laboratorios Salvat, S. A. Oftalmični lokalni sestavek, ki vsebuje dobesilno kislino za zdravljenje bolezni posteriornega očesnega segmenta
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2024226667A2 (en) * 2023-04-24 2024-10-31 Nanoscope Therapeutics Inc. Optogenetic modulation by multi-characteristic opsins for vision restoration and other applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
CA2287495A1 (en) 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
WO2000015822A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
AU2003249318A1 (en) 2002-07-18 2004-02-09 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
JP2007527738A (ja) 2003-11-05 2007-10-04 ニューロヴィジョン， インコーポレイテッド 視覚を改善するための方法および装置
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
EP2019588A4 (en) 2006-05-04 2010-11-24 Univ Wayne State RESTORATION OF VISUAL RESPONSES BY IN VIVO ADMINISTRATION OF NUCLEIC ACIDS OF RHODOPSIN
WO2011140279A1 (en) * 2010-05-04 2011-11-10 Wayne State University Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
PL2614079T3 (pl) * 2010-09-08 2016-01-29 Max Planck Gesellschaft Zmutowana kanałowa rodopsyna 2
AU2013230112A1 (en) * 2012-03-05 2014-09-25 Wayne State University Identification of channelrhodopsin-2 (Chop2) mutations and methods of use
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
AU2019216638B2 (en) 2021-07-08
PL2822964T3 (pl) 2019-05-31
AU2017239601A1 (en) 2017-10-26
AU2021245195B2 (en) 2023-09-28
US20250066431A1 (en) 2025-02-27
HUE040487T2 (hu) 2019-03-28
HK1205744A1 (en) 2015-12-24
CN111378020A (zh) 2020-07-07
US10947281B2 (en) 2021-03-16
AU2013230112A1 (en) 2014-09-25
WO2013134295A1 (en) 2013-09-12
CN104334575A (zh) 2015-02-04
AU2021245195A1 (en) 2021-11-04
MX2014010664A (es) 2015-03-06
MX360085B (es) 2018-10-10
NZ629843A (en) 2017-03-31
NZ727041A (en) 2022-01-28
AU2017239601B2 (en) 2019-05-16
CA2866405A1 (en) 2013-09-12
KR102137717B1 (ko) 2020-07-27
EP2822964B1 (en) 2018-08-22
KR20140132401A (ko) 2014-11-17
JP2018134098A (ja) 2018-08-30
JP2019193656A (ja) 2019-11-07
AU2019216638A1 (en) 2019-09-05
ES2703324T3 (es) 2019-03-08
JP2015510759A (ja) 2015-04-13
US20150044181A1 (en) 2015-02-12
EP2822964A1 (en) 2015-01-14
PT2822964T (pt) 2018-11-29
US20220033449A1 (en) 2022-02-03
EA201491643A1 (ru) 2015-02-27
DK2822964T3 (en) 2018-12-10

Similar Documents

Publication Publication Date Title
JP6395611B2 (ja) チャネルロドプシン−２（Ｃｈｏｐ２）の変異の同定および使用法
JP6511066B2 (ja) 遺伝子治療を用いた網膜変性の処置
US20240165198A1 (en) Optogenetic visual restoration using chrimson
US20230159609A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
Batabyal et al. Multi-characteristic opsin therapy to functionalize retina, attenuate retinal degeneration, and restore vision in mouse models of retinitis pigmentosa
JP6779546B2 (ja) 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
HK1205744B (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
US20230338581A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
US20260048089A1 (en) G-protein-gated-k+ channel-mediated enhancements in light sensitivity in rod-cone dystrophy (rcd)
EA043449B1 (ru) ИДЕНТИФИКАЦИЯ МУТАЦИЙ КАНАЛ-ОПСИНА-2 (Chop2) И СПОСОБЫ ПРИМЕНЕНИЯ
NZ727041B2 (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180423

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180809

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180828

R150 Certificate of patent or registration of utility model

Ref document number: 6395611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250